Combined treatment with infliximab and azathioprine for one year appears to produce more benefits than risks among Crohn's disease patients, according to an analysis in Clinical Gastroenterology and Hepatology. Researchers found that the IFX/AZA combination was more effective than IFX monotherapy in treating the disease. The study was based on data from the Study of Biologic and Immunomodulator-Naive Patients With Crohn's Disease.

Full Story:

Related Summaries